Peter Vanderklish

Peter Vanderklish

Company: Spinogenix

Job title: Chief Scientific Officer


Developing a Synaptic Regenerative Therapy in ALS Using a Novel Spinogenic Small Molecule 4:00 pm

ALS is a synaptopathy that involves an early and progressive loss of glutamatergic synapses in motor and cognitive centers Developing novel small molecule therapeutics for the synaptopathies that regenerate lost synapses to physiologically relevant levels and has a lead clinical candidate (SPG302) selected for ALS In preclinical studies, SPG302 improved motor function and survival in…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.